{"id":1063543,"date":"2010-06-21T08:15:39","date_gmt":"2010-06-21T08:15:39","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/oncomed-has-wnt-in-its-sails\/"},"modified":"2024-08-17T20:30:25","modified_gmt":"2024-08-18T00:30:25","slug":"oncomed-has-wnt-in-its-sails-2","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/oncomed-has-wnt-in-its-sails-2.php","title":{"rendered":"OncoMed Has &#8216;Wnt&#8217; in its Sails"},"content":{"rendered":"<p><a title=\"OncoMed Has 'Wnt' in its Sails; Bayer Deal Adds $40M Up Front\" href=\"http:\/\/www.bioworld.com\/servlet\/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&amp;forceid=54871\" target=\"_blank\" rel=\"noopener\">OncoMed Has 'Wnt' in its Sails; Bayer Deal Adds $40M Up Front<\/a> by Jennifer Boggs, <em>Bioworld<\/em>, June 18, 2010. Excerpts: <\/p><blockquote><p>[OncoMed's] latest accomplishment is another early stage deal, this time with Bayer Schering Pharma AG, to develop drugs targeting the Wnt signaling pathway. It's an agreement that brings $40 million up front, with the potential for more than $1 billion in future milestones.<\/p><\/blockquote><blockquote><p>.....<\/p><\/blockquote><blockquote><p>The Wnt pathway is believed to be a key target in halting cancer stem cell activity. But only a few other firms - Avalon Pharmaceuticals Inc. (now part of Clinical Data Inc.) and 2008 start-up Wintherix LLC, for example - have entered that space, largely because Wnt is not an easily druggable target.<\/p><\/blockquote><p>News release from Bayer: <a title=\"Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics\" href=\"http:\/\/www.bayer.com\/en\/News-Detail.aspx?id=13102\" target=\"_blank\" rel=\"noopener\">Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics<\/a>, June 17, 2010. Excerpt: <\/p><blockquote><p>Bayer Schering Pharma AG, Germany, and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer and agents targeting the Wnt pathway have the potential to be developed as pan-tumor drugs.<\/p><\/blockquote><p><span>Comment<\/span>: The Bayer-OncoMed strategic alliance has received attention via the social media. See, for example, the results of this <a title=\"FriendFeed search\" href=\"http:\/\/friendfeed.com\/search?q=Bayer+OncoMed+cancer+stem+cell\" target=\"_blank\" rel=\"noopener\">FriendFeed search<\/a>.<\/p><div><img loading=\"lazy\" decoding=\"async\" width=\"1\" height=\"1\" src=\"https:\/\/www.immortalitymedicine.tv\/wp-content\/plugins\/wp-o-matic\/cache\/e783d_35997458635844014-7515011688293345443?l=cancerstemcellnews.blogspot.com\" alt=\"\" style=\"padding-left:10px; padding-right: 10px;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>OncoMed Has 'Wnt' in its Sails; Bayer Deal Adds $40M Up Front by Jennifer Boggs, Bioworld, June 18, 2010. Excerpts: [OncoMed's] latest accomplishment is another early stage deal, this time with Bayer Schering Pharma AG, to develop drugs targeting the &hellip; <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/oncomed-has-wnt-in-its-sails-2.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[25,1246878],"tags":[],"class_list":["post-1063543","post","type-post","status-publish","format-standard","hentry","category-stem-cell-therapy","category-stem-cells"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063543"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1063543"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063543\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1063543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1063543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1063543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}